Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.
加利福尼亞州聖地亞哥和中國太倉，2024年7月1日（GLOBE NEWSWIRE）——Connect Biopharma Holdings Limited（納斯達克股票代碼：CNTB）（Connect或公司）是一家總部位於美國的全球臨床階段生物製藥公司，致力於通過開發源自T細胞研究的療法來改善慢性炎症性疾病患者的生活。該公司今天宣佈，首席執行官大衛·斯夸特首席執行官巴里·夸特總裁澤克雷斯和首席財務官史蒂芬·陳將在Leerink Partners主持一對一的投資者會議炎症與免疫學（I&I）和代謝治療論壇將於2024年7月9日至10日在馬薩諸塞州波士頓舉行。
About Connect Biopharma Holdings Limited
關於 Connect 生物製藥控股有限公司
Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and drug discovery to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company's second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/
Connect Biopharma是一家全球性的臨床階段生物製藥公司，運用其在T細胞生物學和藥物發現方面的專業知識，開發治療慢性炎症性疾病的創新療法，目標是改善全球數百萬受影響者的生活。該公司正在建立專有小分子和抗體產品線，使用功能性T細胞檢測，對照經過驗證的免疫靶標篩選和發現有效的候選產品。該公司的主要候選產品rademikibart（前身爲 CBP-201）是一種抗體，旨在靶向正在開發的用於治療特應性皮炎和哮喘的白介素-4受體α受體（IL-4Rα）。該公司的第二種候選產品icanbelimod（前身爲 CBP-307）是S1P1 T細胞受體的調節劑，正在開發用於治療潰瘍性結腸炎（UC）。欲了解更多信息，請訪問： https://www.connectbiopharm.com/
INVESTOR CONTACT:
投資者聯繫人：
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
蒂姆·麥卡錫
生命科學顧問
tim@lifesciadvisors.com
譯文內容由第三人軟體翻譯。